Potential mutagenicity, embryotoxicity, and teratogenicity of calcium ketopantoyl aminobutyrate.

We studied mutagenic, embryotoxic, and teratogenic properties of calcium ketopantoyl aminobutyrate, a preparation proposed as a new drug. Long-term oral administration of calcium ketopantoyl aminobutyrate produced no mutagenic, embryotoxic, and teratogenic effects.

Allergic and immunotoxic effects of calcium ketopantoyl aminobutyrate.

We studied the allergic and immunotoxic effects of a new promising medicinal preparation calcium ketopantoyl aminobutyrate. Calcium ketopantoyl aminobutyrate produced no negative effects on general mechanisms of humoral and cellular immunity. This preparation did not modulate the anaphylactic reaction to bovine serum, exhibited no mitostatic and lymphotoxic properties, had no effect on the delayed-type hypersensitivity response, and did not produce active cutaneous anaphylactic reaction.

[Comparative investigation of calcium ketopantoylaminobutyrate and pantogam: tranquilizer activity].

Comparative study of the sedative (calming) properties of the new drug calcium ketopantoylaminobutyrate (Ca-KPAB) and the reference drug pantogam (calcium homopantotenate) showed that the newly synthesized compound produces a more pronounced calming action in several standard neuropharmacological tests (spontaneous motor activity, barbiturate antagonist, etc.) and exhibits some additional advantages. Thus, a slight modification of the chemical structure made possible a significant reduction in the effective drug dose.

[Toxicological characterization of calcium ketopantoylaminobutyrate].

The investigation of toxicity of calcium ketopantoylaminobutyrate (Ca-KPAB) showed that this newly synthesized compound belongs to the class of low-toxicity substances. The LD 50 of Ca-KPAB for oral administration is lower than that of pantogam. No toxicity manifestations and local irritant activity was observed upon chronic administration of Ca-KPAB.

[A comparative study of the permeability across the hemato-encephalic barrier and of the effect on cerebral blood flow of the new neurotropic agent calcium ketohomopantothenate and of pantogam].

The permeability through the blood-brain barrier of N-(4-hydroxy-3,3 dimethyl-2-oxo-1-butiryl) gamma-aminobutyric acid calcium salt, a new neurotropic drug calcium ketohomopantothenate (KPA-Ca), was studied in comparison with that of calcium homopantothenate, pantogam (P) Liquid chromatography analysis showed that after oral administration of KPA-Ca and P both forms of these agents, namely, oxy- and keto- derivatives of homopantothenic acid, were found in the brain of experimental rats, the KPA-Ca (ketoform) content being higher. Pharmacological studies showed that KPA-Ca penetrates the blood-brain barrier in greater amounts and causes a higher effect on the rate of cerebral blood flow when it is administered per os in a dose of 50 mg/kg.